blue cross blue shield glp-1 coverage 2025 of Massachusetts will stop covering popular drugs for weight loss. Here's why GLP-1 Drugs: What Employers Need

The Category 1 status is provisional pending PCAC review before end of February 2027

Semaglutide storage Semaglutide requires careful attention to storage because of its widespread use in weight loss and body composition research

Clinical trials show semaglutide produces 14.9% average body weight reduction over 68 weeks, whereas Lipo C alone (without concurrent deficit) produces no measurable fat loss

Chodurek, and Z

They help to regulate blood sugar levels and support weight loss, and are only available following a medical consultation due to their strength and clinical profile

Who should consider GLP-1 drugs for weight loss